Strategies to Reduce Morbidity and Mortality in COPD: A Patient-focused Approach for Integration of Combination and Triple Therapy – Pretest

1. How confident are you in the management of patients with COPD in your practice?

2. The features of breathlessness that suggest a diagnosis of COPD in individuals aged 40 years and older include:

3. A patient presents to your office following discharge from a hospitalization consistent with a COPD exacerbation. The patient has no previous COPD diagnosis. Spirometry reveals a postbronchodilator FEV1/FVC of 0.62 and a FEV1 58% predicted. The patient has no prior exacerbation history and states she experiences shortness of breath while walking slower than people of her age. Based on this information, which GOLD group is most appropriate for this patient?

4. The recent ATS pharmacotherapy recommendations makes a strong recommendation for initial LABA + LAMA combination therapy rather than monotherapy in which of the following?

5. Recently published data from 2 trials demonstrated a mortality benefit for patients with COPD on inhaled triple therapy vs dual bronchodilator therapy. The mean FEV1 at baseline for the patient populations in both trials was which of the following?